Lilly sued by Mississippi over Zyprexa marketing

The state of Mississippi is seeking $100 million from Eli Lilly over the company’s alleged improper marketing of Zyprexa – the fifth such lawsuit filed by a state concerning marketing of the drug. Mississippi charges that Lilly promoted the drug for unapproved uses, including for children. “We certainly don’t want to bankrupt a company,” Attorney General Jim Hood told The Indianapolis Star, “but at the same time we have a duty to get what the state’s owed.” Hood’s claim includes money spent on Zyprexa to treat the unapproved symptoms, as well as reimbursement for diabetes-related injuries the drug caused some Medicaid recipients. "Because we haven't been served with the lawsuit, we cannot comment, Terra Fox, a Lilly spokesman, told MM&M. Second-quarter sales of Zyprexa, on the market since 1996, totaled $1.12 billion, a 2% increase year-over-year. US Zyprexa sales fell 1% to $542.9 million. Mississippi is likely to work together with the other states that have sued: Louisiana, Florida, Alaska and most recently West Virginia. Last year Lilly paid $1 billion to settle 10,500 US legal claims by Zyprexa users alleging they suffered diabetes-related injuries from the drug. Another 5,500 claims are pending from US users, plus five class-action lawsuits in Canada.
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.